share_log

Medicines and Healthcare products Regulatory Agency Grants Marketing Authorization for Novartis' Radioligand Therapy Pluvicto (Lutetium (¹⁷⁷lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britain

Medicines and Healthcare products Regulatory Agency Grants Marketing Authorization for Novartis' Radioligand Therapy Pluvicto (Lutetium (¹⁷⁷lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britain

藥品和保健品監管機構批准諾華公司的放射配基治療Pluvicto(Lutetium(?⁷⁷lu)Vipivotie Tetxetan)在英國晚期前列腺癌中的營銷授權
Benzinga Real-time News ·  2022/08/12 04:56

Medicines and Healthcare products Regulatory Agency Grants Marketing Authorization for Novartis' Radioligand Therapy Pluvicto (Lutetium (¹⁷⁷lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britain

藥品和保健品監管機構批准諾華公司的放射配基治療Pluvicto(Lutetium(?⁷⁷lu)Vipivotie Tetxetan)在英國晚期前列腺癌中的營銷授權

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論